vs
Bank7 Corp.（BSVN）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Bank7 Corp.的1.5倍（$35.5M vs $24.1M），Bank7 Corp.净利率更高（44.7% vs -304.2%，领先349.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -0.1%），Bank7 Corp.自由现金流更多（$41.4M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 0.2%）
Bank7 Corp是美国的金融控股公司，旗下运营全服务社区银行Bank7，提供商业及个人银行产品，包括存款账户、小微企业贷款、商业地产融资及个人贷款解决方案，核心服务区域覆盖俄克拉荷马州、得克萨斯州、堪萨斯州，客群以中小企业和零售客户为主。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BSVN vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.5倍
$24.1M
营收增速更快
RXRX
高出681.9%
-0.1%
净利率更高
BSVN
高出349.0%
-304.2%
自由现金流更多
BSVN
多$88.7M
$-47.3M
两年增速更快
RXRX
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.1M | $35.5M |
| 净利润 | $10.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 58.7% | -304.8% |
| 净利率 | 44.7% | -304.2% |
| 营收同比 | -0.1% | 681.7% |
| 净利润同比 | -2.9% | 39.6% |
| 每股收益（稀释后） | $1.13 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSVNRXRX
| Q4 25 | $24.1M | $35.5M | ||
| Q3 25 | $25.2M | $5.2M | ||
| Q2 25 | $24.4M | $19.2M | ||
| Q1 25 | $22.6M | $14.7M | ||
| Q4 24 | $24.1M | $4.5M | ||
| Q3 24 | $24.9M | $26.1M | ||
| Q2 24 | $24.4M | $14.4M | ||
| Q1 24 | $24.0M | $13.8M |
净利润BSVNRXRX
| Q4 25 | $10.8M | $-108.1M | ||
| Q3 25 | $10.8M | $-162.3M | ||
| Q2 25 | $11.1M | $-171.9M | ||
| Q1 25 | $10.3M | $-202.5M | ||
| Q4 24 | $11.1M | $-178.9M | ||
| Q3 24 | $11.8M | $-95.8M | ||
| Q2 24 | $11.5M | $-97.5M | ||
| Q1 24 | $11.3M | $-91.4M |
毛利率BSVNRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率BSVNRXRX
| Q4 25 | 58.7% | -304.8% | ||
| Q3 25 | 56.2% | -3327.6% | ||
| Q2 25 | 60.2% | -916.8% | ||
| Q1 25 | 60.7% | -1297.9% | ||
| Q4 24 | 61.0% | -4042.4% | ||
| Q3 24 | 62.2% | -377.1% | ||
| Q2 24 | 62.5% | -697.4% | ||
| Q1 24 | 62.0% | -698.4% |
净利率BSVNRXRX
| Q4 25 | 44.7% | -304.2% | ||
| Q3 25 | 43.0% | -3135.3% | ||
| Q2 25 | 45.4% | -894.2% | ||
| Q1 25 | 45.7% | -1373.3% | ||
| Q4 24 | 46.0% | -3935.5% | ||
| Q3 24 | 47.3% | -367.5% | ||
| Q2 24 | 47.2% | -676.6% | ||
| Q1 24 | 47.0% | -662.4% |
每股收益（稀释后）BSVNRXRX
| Q4 25 | $1.13 | $-0.17 | ||
| Q3 25 | $1.13 | $-0.36 | ||
| Q2 25 | $1.16 | $-0.41 | ||
| Q1 25 | $1.08 | $-0.50 | ||
| Q4 24 | $1.16 | $-0.56 | ||
| Q3 24 | $1.24 | $-0.34 | ||
| Q2 24 | $1.23 | $-0.40 | ||
| Q1 24 | $1.21 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $251.0M | $1.1B |
| 总资产 | $2.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资BSVNRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务BSVNRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益BSVNRXRX
| Q4 25 | $251.0M | $1.1B | ||
| Q3 25 | $241.7M | $1.0B | ||
| Q2 25 | $231.9M | $919.1M | ||
| Q1 25 | $221.7M | $933.9M | ||
| Q4 24 | $213.2M | $1.0B | ||
| Q3 24 | $204.2M | $524.6M | ||
| Q2 24 | $190.8M | $584.4M | ||
| Q1 24 | $180.4M | $401.2M |
总资产BSVNRXRX
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.9B | $1.4B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.7B | $1.4B | ||
| Q3 24 | $1.7B | $726.5M | ||
| Q2 24 | $1.7B | $775.9M | ||
| Q1 24 | $1.8B | $557.8M |
负债/权益比BSVNRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $41.4M | $-47.3M |
| 自由现金流率自由现金流/营收 | 171.7% | -133.1% |
| 资本支出强度资本支出/营收 | 19.7% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.28× | — |
| 过去12个月自由现金流最近4个季度 | $74.8M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流BSVNRXRX
| Q4 25 | $46.1M | $-46.1M | ||
| Q3 25 | $16.6M | $-117.4M | ||
| Q2 25 | $9.4M | $-76.4M | ||
| Q1 25 | $11.0M | $-132.0M | ||
| Q4 24 | $55.0M | $-115.4M | ||
| Q3 24 | $13.4M | $-59.2M | ||
| Q2 24 | $8.1M | $-82.2M | ||
| Q1 24 | $20.4M | $-102.3M |
自由现金流BSVNRXRX
| Q4 25 | $41.4M | $-47.3M | ||
| Q3 25 | $16.4M | $-117.6M | ||
| Q2 25 | $8.8M | $-79.6M | ||
| Q1 25 | $8.2M | $-133.8M | ||
| Q4 24 | $50.8M | $-116.7M | ||
| Q3 24 | $12.7M | $-63.8M | ||
| Q2 24 | $6.5M | $-83.4M | ||
| Q1 24 | $19.8M | $-109.0M |
自由现金流率BSVNRXRX
| Q4 25 | 171.7% | -133.1% | ||
| Q3 25 | 65.0% | -2272.5% | ||
| Q2 25 | 36.1% | -413.9% | ||
| Q1 25 | 36.3% | -907.4% | ||
| Q4 24 | 210.6% | -2567.7% | ||
| Q3 24 | 51.2% | -244.6% | ||
| Q2 24 | 26.8% | -578.5% | ||
| Q1 24 | 82.3% | -789.9% |
资本支出强度BSVNRXRX
| Q4 25 | 19.7% | 3.5% | ||
| Q3 25 | 0.8% | 4.7% | ||
| Q2 25 | 2.6% | 16.4% | ||
| Q1 25 | 12.4% | 12.4% | ||
| Q4 24 | 17.4% | 28.6% | ||
| Q3 24 | 2.5% | 17.5% | ||
| Q2 24 | 6.6% | 8.2% | ||
| Q1 24 | 2.8% | 48.2% |
现金转化率BSVNRXRX
| Q4 25 | 4.28× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 1.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
